Six-month triptorelin depot injection now available

As Decapeptyl SR 22.5mg is a suspension of microparticles, intravascular injection must be strictly avoided
As Decapeptyl SR 22.5mg is a suspension of microparticles, intravascular injection must be strictly avoided

Ipsen has added a six-month triptorelin depot injection to its Decapeptyl SR range.

The 22.5mg presentation is licensed for the treatment of metastatic prostate cancer and for locally advanced, non-metastatic prostate cancer as an alternative to surgical castration.

It is supplied as a powder and solvent for suspension, to be administered by intramuscular injection.

Decapeptyl SR is also available in 1-monthly (3mg) and 3-monthly (11.25mg) presentations for the treatment of precocious puberty and endometriosis.

View Decapeptyl SR drug record

Further information: Ipsen

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...